Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study
Background: Clinical pharmacy services in the critical health care settings have expanded dramatically.Study problem.Clinical pharmacy services have limited implementation in Palestine. Many intensive care units (ICUs) patients do not get the intended beneficial effects of their treatment due to tre...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-12-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016422002481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308306703646720 |
|---|---|
| author | Aseel Houso Motasem Hamdan Hiba Falana |
| author_facet | Aseel Houso Motasem Hamdan Hiba Falana |
| author_sort | Aseel Houso |
| collection | DOAJ |
| description | Background: Clinical pharmacy services in the critical health care settings have expanded dramatically.Study problem.Clinical pharmacy services have limited implementation in Palestine. Many intensive care units (ICUs) patients do not get the intended beneficial effects of their treatment due to treatment related problems and their consequent cost burden. Aim: To evaluate the impact of the clinical pharmacist interventions on costs of care and safety of patient by assessing treatment related problems among medical ICUs patients in Palestine. Methodology: A prospective interventional study was conducted at medical ICU of the major public hospital in Ramallah city over a 4-month period (between September and December 2020). Patients were randomly assigned to either an intervention or a control group (With / without clinical pharmacist involvement). Treatment related problems were identified in both study groups by the clinical pharmacist, but interventions were only provided to the intervention group. The total economic benefit included both cost savings from intervention and cost avoidance from preventable adverse drug events (ADEs) resulted from CP interventions. The primary outcomes with the clinical pharmacist interventions were net benefit and benefit to cost ratio, which were calculated using previously published methodologies and adjusted to the Palestinian settings. The analysis of CP interventions acceptance by physicians was performed. Results: During the 4-month study period, the 117 patients admitted to the ICU were included into the analysis; 66 patients in the intervention group and 51 in the control group. The interventions made by a clinical pharmacist resulted in direct cost saving of NIS8,990.05 ($2799.63) and cost avoidance of NIS22,087.5 ($ 6878.37). Translated into a net savings of NIS188.35 ($58.65) per intervention and NIS470 ($146.36) per patient. Comparison of benefits (NIS31,077.55) ($9678.00) and costs (NIS19,043.928) ($5930.55) indicate a net economic benefit to the institution of (NIS 12,033.623) ($3747.44) and a benefit cost ratio of 1.63. Conclusion: Integrating a clinical pharmacist in the ICU team was investment that resulted in benefits in term of cost saving and cost avoidance. |
| format | Article |
| id | doaj-art-150119500a164a12a7e6adc1d2bf1d3e |
| institution | Kabale University |
| issn | 1319-0164 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj-art-150119500a164a12a7e6adc1d2bf1d3e2025-08-20T03:54:29ZengSpringerSaudi Pharmaceutical Journal1319-01642022-12-0130121718172410.1016/j.jsps.2022.09.017Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional studyAseel Houso0Motasem Hamdan1Hiba Falana2Faculty of Public Health, Al-Quds University, Jerusalem, Palestine; Corresponding author.Faculty of Public Health, Al-Quds University, Jerusalem, PalestineFaculty of pharmacy, Birzait University Ramallah, PalestineBackground: Clinical pharmacy services in the critical health care settings have expanded dramatically.Study problem.Clinical pharmacy services have limited implementation in Palestine. Many intensive care units (ICUs) patients do not get the intended beneficial effects of their treatment due to treatment related problems and their consequent cost burden. Aim: To evaluate the impact of the clinical pharmacist interventions on costs of care and safety of patient by assessing treatment related problems among medical ICUs patients in Palestine. Methodology: A prospective interventional study was conducted at medical ICU of the major public hospital in Ramallah city over a 4-month period (between September and December 2020). Patients were randomly assigned to either an intervention or a control group (With / without clinical pharmacist involvement). Treatment related problems were identified in both study groups by the clinical pharmacist, but interventions were only provided to the intervention group. The total economic benefit included both cost savings from intervention and cost avoidance from preventable adverse drug events (ADEs) resulted from CP interventions. The primary outcomes with the clinical pharmacist interventions were net benefit and benefit to cost ratio, which were calculated using previously published methodologies and adjusted to the Palestinian settings. The analysis of CP interventions acceptance by physicians was performed. Results: During the 4-month study period, the 117 patients admitted to the ICU were included into the analysis; 66 patients in the intervention group and 51 in the control group. The interventions made by a clinical pharmacist resulted in direct cost saving of NIS8,990.05 ($2799.63) and cost avoidance of NIS22,087.5 ($ 6878.37). Translated into a net savings of NIS188.35 ($58.65) per intervention and NIS470 ($146.36) per patient. Comparison of benefits (NIS31,077.55) ($9678.00) and costs (NIS19,043.928) ($5930.55) indicate a net economic benefit to the institution of (NIS 12,033.623) ($3747.44) and a benefit cost ratio of 1.63. Conclusion: Integrating a clinical pharmacist in the ICU team was investment that resulted in benefits in term of cost saving and cost avoidance.http://www.sciencedirect.com/science/article/pii/S1319016422002481Clinical PharmacyCost benefit analysisTreatment related problemsIntensive care unit(ICU)Clinical pharmacist interventionsRamallah |
| spellingShingle | Aseel Houso Motasem Hamdan Hiba Falana Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study Saudi Pharmaceutical Journal Clinical Pharmacy Cost benefit analysis Treatment related problems Intensive care unit(ICU) Clinical pharmacist interventions Ramallah |
| title | Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study |
| title_full | Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study |
| title_fullStr | Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study |
| title_full_unstemmed | Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study |
| title_short | Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study |
| title_sort | cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in palestine medical complex prospective interventional study |
| topic | Clinical Pharmacy Cost benefit analysis Treatment related problems Intensive care unit(ICU) Clinical pharmacist interventions Ramallah |
| url | http://www.sciencedirect.com/science/article/pii/S1319016422002481 |
| work_keys_str_mv | AT aseelhouso costbenefitanalysisofclinicalpharmacistinterventionsinmedicalintensivecareunitinpalestinemedicalcomplexprospectiveinterventionalstudy AT motasemhamdan costbenefitanalysisofclinicalpharmacistinterventionsinmedicalintensivecareunitinpalestinemedicalcomplexprospectiveinterventionalstudy AT hibafalana costbenefitanalysisofclinicalpharmacistinterventionsinmedicalintensivecareunitinpalestinemedicalcomplexprospectiveinterventionalstudy |